Bloomberg

Recent Articles

Pet Food Makers Think Beyond Animal Meat

As concerns grow about the climate impact of meat, startups look to make more dog and cat foods that are plant-based, made from insects, or lab-grown.

By Coco Liu / Bloomberg February 6, 2023

Inside the Race to Get PFAS Chemicals Out of Raincoats

Many commercially available raincoats contain PFAS—"forever chemicals." Manufacturers are working to develop new, PFAS-free materials.

By Zahra Hirji and Olivia Rockeman / Bloomberg February 2, 2023

Energy Department Enters the Gas Stove Debate

The Department of Energy set new limits on energy consumption for gas stoves, which could have an impact on the products' future.

By Ari Natter / Bloomberg February 2, 2023

Why Hong Kong Is Giving Away Half a Million Airline Tickets

The move is part of a global publicity campaign unveiled Thursday to revive the city's struggling tourism sector.

By Shirley Zhao and Felix Tam / Bloomberg February 2, 2023

Shell Posts Record 2022 Profit Fueled By Soaring Energy Prices

The earnings are the latest evidence of a blowout year for Big Oil, with Exxon Mobil Corp. also reporting a record annual profit in recent days.

By William Mathis / Bloomberg February 2, 2023

Teen Detained in Singapore for Planning ISIS-Inspired Attack

An 18-year-old student was arrested in December after authorities determined that he posed an “imminent security threat.”

By Sing Yee Ong / Bloomberg February 2, 2023

No More Free Option for New Subscribers to Peacock

While existing subscribers to the streaming service’s free tier can still view programming, new customers must now choose between two paid plans.

By Christopher Palmeri / Bloomberg January 31, 2023

Most Americans Aren’t Getting Enough Exercise, Study Finds

Less than a third of U.S. adults meet suggested benchmarks for aerobic and muscle-building activities set out by health officials.

By Tanaz Meghjani/Bloomberg January 27, 2023

Evusheld Loses U.S. Authorization Since It's Not Effective Against New Variants

AstraZeneca's COVID-19 antibody drug, Evusheld, lost its authorization since it’s unlikely to work against current strains.

By Madison Muller/Bloomberg January 27, 2023

Australia Investigates Online Influencers Over False Advertising

Many of the accounts under investigation offer beauty, lifestyle, parenting and fashion advice, potentially without disclosing sponsorships or affiliations with particular companies and brands.

By Ben Westcott / Bloomberg January 26, 2023
More from TIME
More From TIME